<DOC>
	<DOCNO>NCT02117167</DOCNO>
	<brief_summary>Open label multicentric randomize phase II trial , use high throughput genome analysis therapeutic decision tool , aim comparing target treatment administer accord identify molecular anomaly tumor standard treatment ( pemetrexed Non-squamous patient erlotinib squamous cell , target substudy 1 ) well immunotherapy maintenance therapy patient without actionable genomic alteration non eligible substudy 1 ( immune substudy 2 ) .</brief_summary>
	<brief_title>SAFIR02_Lung - Efficacy Targeted Drugs Guided Genomic Profils Metastatic NSCLC Patients</brief_title>
	<detailed_description>Screening phase : New frozen biopsy archive frozen sample send genomic plateforms DNA extraction genomic analysis ( DNA microarrays Next generation sequence ) . Patients consider pre-eligible target substudy 1 randomisation phase follow mandatory condition meet : stable respond disease observe 4 cycle chemotherapy ( investigator judgment ) targetable alteration identify Molecular tumor board ( MTB ) . If eligible substudy 1 randomisation phase , patient consider pre-eligible immune substudy 2 randomization phase follow mandatory condition meet : stable respond disease ( investigator judgment ) observe 4 cycle platinum-based chemotherapy AND eligible randomization substudy 1 ( patient targetable alteration identify Molecular Tumor Board , fail genomic profile tumor [ low tumor cell percentage , technical issue genomic analysis , etc . ] , non-inclusion criterion preclude entry substudy 1 ) Randomization phase : The mandatory post-chemotherapy 28-day wash-out period follow cycle 4 chemotherapy provide time achieve require test examination . The randomization program allocate follow treatment 2:1 ratio favor Arm A consider substudy : Substudy 1 : target therapy versus standard maintenance therapy - Arm A1 / target arm : targeted maintenance list 6 target drug guide genomic analysis , - Arm B1 / standard arm : standard maintenance ( pemetrexed non-squamous erlotinib squamous NSCLC ) . Substudy 2 : immunotherapy versus standard maintenance therapy - Arm A2 / immunotherapy maintenance arm : MEDI4736 - Arm B2 / standard arm : standard maintenance ( pemetrexed non-squamous erlotinib squamous NSCLC ) .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Screening phase : histologically proven NSCLC Metastatic relapse stage IV diagnosis , stage IIIb amenable surgery radiotherapy No EGFRactivating mutation ALK translocation primary tumor metastasis biopsied , exclude bone . Age &gt; 18 year WHO Performance Status 0/1 Chemonaïve patient eligible first line platinumbased chemotherapy No tumor progression observe current line treatment measurable target lesion evaluable disease RECIST Exclusion criterion Spinal cord compression and/or symptomatic progressive brain metastasis Abnormal coagulation contraindicate biopsy Inability swallow Major problem intestinal absorption Any clinically important abnormality rhythm , conduction morphology rest ECG Any factor increase risk QTc prolongation arrhythmic event Experience follow precede 12 month : coronary artery bypass graft , angioplasty , vascular stent , myocardial infarction , past current uncontrolled angina pectoris , congestive heart failure NYHA Grade ≥2 , torsades de pointes , current uncontrolled hypertension , cardiomyopathy Past medical history interstitial lung disease , druginduced interstitial disease , radiation pneumonitis require steroid treatment evidence clinically interstitial lung disease Previous current malignancy histology within last 5 year , Evidence severe uncontrolled systemic disease ( active bleeding diatheses , active Hepatitis B , C HIV ) Diagnosis diabetes mellitus type I II diagnosis acne rosacea , severe psoriasis severe atopic eczema Prior exposure anthracyclines mitoxantrone cumulative exposure excess 360 mg/m² doxorubicin , 720 mg/m² epirubicin , 72 mg/m² mitoxantrone History retinal degenerative disease , eye injury corneal surgery previous 3 month , past history central serous retinopathy retinal vein occlusion , intraocular pressure &gt; 21 mmHg , uncontrolled glaucoma . History heamorrhagic thrombotic stroke , TIA CNS bleed Renal disease include glomerulonephritis , nephritic syndrome , Fanconi syndrome , renal tubular acidosis Patients use drug know potent inhibitor potent inducer substrates cytochrome P450 Randomized phase : Substudy 1 : Inclusion criterion Patients receive 4 cycle induction platinumbased chemotherapy SD PR randomization present least one genomic alteration predefined list Age &gt; 25 year patient plan receive AZD4547 28day washout period chemo prior randomization grade ≤1 residual toxicity Exclusion criterion Life expectancy &lt; 3 month Disease progression occur time chemotherapy randomization toxicity lead discontinuation platinium base chemotherapy 4 full cycle deliver Less 28 day radiotherapy , less 2 week palliative radiation Patients previously treat targeted agent class agent test study Toxicities grade ≥2 previous anticancer therapy Altered haematopoietic organ function Mean resting correct QT interval ( QTc ) &gt; 480msec ( QTcF &gt; 450 msec ) obtain 3 consecutive ECGs LVEF &lt; 55 % ( MUGA scan Echocardiogram ) , Altered ophthalmic condition confirm ophthalmology specialist patient likely treat AZD4547 orAZD8931 Selumetinib Patients use nonsubstitutable drug , know prolong QT interval induce Torsades de Pointes , suppose treat vandetanib , AZD5363 AZD8931 Substudy 2 : Inclusion criterion Patients receive 4 cycle induction platinumbased chemotherapy SD PR randomization Patients eligible substudy 1 28day washout period chemo prior randomization grade ≤1 residual toxicity Exclusion criterion Life expectancy &lt; 3 month Disease progression occur time chemotherapy randomization toxicity lead discontinuation platinium base chemotherapy 4 full cycle deliver Any previous treatment PD1 PDL1 inhibitor , include MEDI4736 Toxicities grade ≥2 previous anticancer therapy Altered haematopoietic organ function Mean rest QT interval correct heart rate ( QTc ) ≥470 m calculate 3 consecutive ECGs use Bazett 's Correction Current prior use immunosuppressive medication within 28 day first dose MEDI4736 , exception intranasal inhaled corticosteroid systemic corticosteroid physiological dos , exceed 10 mg/day prednisone , equivalent corticosteroid Active prior document autoimmune disease within past 2 year NOTE : Subjects vitiligo , Grave 's disease , psoriasis require systemic treatment ( within past 2 year ) exclude History primary immunodeficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>